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Abstract 
Background: A novel series of 5-(substituted aldehyde)-7-methyl-3-oxo-N-phenyl-2-((3,4,5,6-tetrahydroxytetrahydro-
2H-pyran-2-yl)methylene)-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-6-carboxamide analogues (1–24) was synthe-
sized using the Biginelli condensation.
Results and discussion: The synthesized compounds were screened for their in vitro antimicrobial potential 
against Gram (positive and negative) bacterial and fungal strains by tube dilution technique. In the series, com-
pound 15 exhibited significant antimicrobial activity against Candida albicans and Aspergillus niger with MIC 
value = 1.04 × 10−2 µM/ml and compound 2 was found to be most active antioxidant agent with IC50 value = 46.31 
using DPPH assay. Anticancer activity results indicated that compound 23 displayed better anticancer activity against 
human breast cancer cell line (MCF-7) with GI50 value = 34.78 using SRB assay.
Conclusions: All synthesized derivatives exhibited good antimicrobial, antioxidant and anticancer activity using 
specific method and compared with standard drugs, especially compounds 2, 15 and 23 displayed more activity 
than reference drugs. Structure activity relationship demonstrated that presence of electron releasing groups of the 
synthesized compounds enhanced the antibacterial activity against Escherichia coli as well as antioxidant activity and 
electron withdrawing groups improved the antimicrobial as well as anticancer activity against human breast (MCF-7) 
cancer cell line.
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Background
Pyrimidines are obtained from the various natural 
resources and synthethic reaction in medicinal chemistry 
[1]. They are also known as m-diazine or 1,3-diazone can 
be considered as cyclic amine. Heterocyclic compounds 
are used in agricultural and medicinal reasons using bio-
logical and chemical studies. Pyrimidine derivatives play 
a vital role in several biological activities i.e. antihyper-
tensive, anticancer, antimicrobial, anti-inflammatory, 
antifungal, analgesic, antioxidant, anticonvulsant and 
antiviral [2]. Antimicrobials agents are one of the most 
important weapons in the resistance of infection caused 
by bacterial strains [3]. In the past few years, increase 
the resistance of microorganisms toward antimicrobial 
agents become a serious health problem so there is a 
need of safe, potent and novel antimicrobial agents [4]. 
Pyrimidine derivatives showed most antimicrobial activ-
ity against Gram +ve and Gram –ve microorganism [5]. 
At that time, many antimicrobial drugs are present in the 
market but due to the indiscriminate use of antimicrobial 
agents often followed the development of resistant strains 
of microorganism so there is a need for the development 
of new class of active antimicrobial drugs with lesser or 
no side effects [6]. Pyrimidine agents recently attracted 
medicinal chemist in exploring their potential as antioxi-
dant agents. Oxidative stress appears to play an impor-
tant role in many human diseases, including cancers. 
The use of antioxidants in pharmacology is intensively 
studied, particularly for stroke and neurodegenerative 
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diseases [7]. Antioxidants are the agents that neutralize 
free radicals, which scavenge reactive oxygen species may 
be high potent value in preventing the onset and propa-
gation of oxidative diseases like neurovascular, autoim-
mune and cardiovascular diseases [8].
Cancer is one of the most serious medical problem 
and second leading cause of death in the world, charac-
terized by a deregulation of the cell cycle which mainly 
results in a progressive loss of cellular differentiation and 
uncontrolled cellular growth. The current situation high-
lights the need for discovery and development of small 
molecule anticancer drugs with improved tumor selec-
tivity, efficacy and safety remains desirable [9]. Many 
pyrimidine derivatives were reported to be active against 
various forms of cancer. Due to less effective, more side 
effect and lack of a broad range of anticancer agents there 
is a need of anticancer agents have motivated the idea 
of researchers toward the discovery of novel anticancer 
agents [10]. Owing to the pharmacological significance of 
pyrimidine derivatives so, we have planned to synthesize 
some new pyrimidine derivatives and evaluate for their 
antimicrobial, antioxidant and anticancer activities.
Results and discussion
Chemistry




dine-6-carboxamide analogues using the Biginelli con-
densation and synthetic steps of this series showing in 
Scheme  1. The physiochemical properties (molecular 
formula; molecular weight; melting points; percentage 
yield etc.) of the synthesized analogues are presented 
in Table  1. The chemical structures of the synthesized 
compounds were confirmed by 1H/13C-NMR, FT-IR, 
Mass spectral and elemental analysis studies. The ele-
mental analysis results of synthesized compounds were 
within ±0.4% of the theoretical values.
Antimicrobial activity
The in  vitro antimicrobial activity of synthesized com-
pounds against Gram-positive bacteria: Staphylococ‑
cus aureus (MTCC 3160), Bacillus subtilis (MTCC 441), 
Gram-negative bacterium: Escherichia coli (MTCC 443) 
and fungal: Candida albicans (MTCC 227) and Asper‑
gillus niger (MTCC 281) strains was examined by tube 
dilution method [11]. Norfloxacin and fluconazole used 
as standard for antibacterial and antifungal activities 
respectively. Dilutions of test and standard compounds 
were prepared in double strength nutrient broth for 
bacterial strains and sabouraud dextrose broth for fungal 
strains [12]. The samples were incubated at 37 ± 1 °C for 
24  h (for bacterial species), at 25 ±  1  °C for 7  days (A. 
niger) and at 37 ± 1 °C for 48 h (C. albicans) respectively 
and the results were recorded in terms of MIC (the low-
est concentration of test substance which inhibited the 
growth of microorganisms). In case of Gram positive bac-
teria, compounds 12 and 14 (MICsa = 2.14 × 10−2 µM/
ml) having significant activity against S. aureus and com-
pound 18 (MICbs = 0.58 × 10−2 µM/ml) exhibited most 
potent against B. subtilis. In case of Gram negative bacte-
rium, compound 21 (MICec = 1.10 × 10−2 µM/ml) dis-
played more potent activity against E. coli. Compound 15 
(MICca & an = 1.04 × 10−2 µM/ml) was found to be most 
potent against C. albicans and A. niger. These compounds 
may be taken as lead to discovery novel antimicrobial 
agents. The presented results are showing in Table 2.
Antioxidant activity
The antioxidant activity of the synthesized compounds 
was evaluated with spectrophotometrically using free 
radical scavenging DPPH assay. The DPPH is a stable 
free radical with maximal absorption at 517  nm and 
is reduced to a corresponding hydrazine when it reacts 
with hydrogen donors. When DPPH reacts with an anti-
oxidant agent, it can donate hydrogen get reduced and 
deep violet colour of DPPH change to yellow, showing a 
considerable decreased in absorption at 517  nm. DPPH 
solution (3 μg/ml) was prepared in methanol (methanol: 
DPPH in 1:1) for blank reference. Four types of dilutions 
were prepared in the methanol of the synthesized deriva-
tives and standard (ascorbic acid) in the concentration of 
25, 50, 75 and 100 μg/ml and then 1 ml of each concen-
tration was added to 1 ml of DPPH solution. The solution 
mixture was shaken vigorously and kept in dark place for 
30 min at room temperature and absorbance was meas-
ured by UV at 517 nm [13]. Free radical DPPH inhibition 
in percentage (%) was calculated as follows:
where, ABlank  =  absorbance of the blank reaction, 
ASample = absorbance of the test compound
IC50 value was calculated from the graph plotted 
between % inhibition and synthesized compound (Figs. 1, 
2, 3). Antioxidant activity demonstrated, compounds 2 and 
16 exhibited excellent activity at absorbance 517 nm with 
IC50 values = 46.31 and 48.81 respectively and compared 
with ascorbic acid as standard drug. These compounds 
may be used as a lead for development of new antioxidant 
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Scheme 1 Synthesis of 5-(substituted aldehyde)-7-methyl-3-oxo-N-phenyl-2-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methylene)-1,2,3,5-
tetrahydroimidazo[1,2-a]pyrimidine-6-carboxamide analogues
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Anticancer activity




6-carboxamide analogues were carried out by sulforho-
damine B (SRB) assay against human breast (MCF-7) 
cancer cell line. All synthesized compounds submitted to 
screen have been tested initially at dose (10−7–10−4 M) at 
anticancer drug screening facility (ACDSF) at ACTREC, 
Tata Memorial Centre, and Mumbai. Among them, com-
pound 23 was found to be most potent anticancer agent 
at dose 10−4 M against human breast (MCF-7) cancer 
cell line and comparable with adriamycin as standard 
(Tables  4, 5). Graph plotted between tested compound 
and standard drug presented in Fig. 4.
SAR (structure activity relationship) studies
From the antimicrobial, antioxidant and anticancer activities 
results of the synthesized 5-(substituted aldehyde)-7-me-
thyl-3-oxo-N-phenyl-2-((3,4,5,6-tetrahydroxytetrahydro-
2H-pyran-2-yl)methylene)-1,2,3,5-tetrahydroimidazo[1,2-a]
pyrimidine-6-carboxamide analogues, the subsequent 
structure activity relationship can be derived in Fig. 5.
  • Presence of electron releasing groups (–OC2H5, 
–OH, Compound 21) on benzylidene portion 
Table 1 The physicochemical properties of  the synthe-
sized analogous
a TLC mobile phase-Benzene
Comp. M. Formula M. Wt. m.p. (°C) Rf value
a % yield
1 C30H28N4O8 572 121–123 0.58 86
2 C29H32N4O10 596 169–171 0.31 83
3 C26H25N5O9 551 159–161 0.53 80
4 C30H35N5O7 577 150–153 0.68 84
5 C26H25N5O9 551 122–124 0.63 91
6 C26H25N5O9 551 159–161 0.51 64
7 C28H31N5O7 549 161–163 0.56 88
8 C26H26N4O8 522 170–172 0.61 84
9 C27H28N4O9 552 146–148 0.41 80
10 C26H24Cl2N4O7 574 148–150 0.42 83
11 C27H28N4O8 536 174–176 0.45 78
12 C26H25BrN4O7 584 144–146 0.66 72
13 C27H28N4O8 536 148–150 0.39 78
14 C26H25BrN4O7 584 155–157 0.38 72
15 C26H25BrN4O8 601 119–121 0.62 90
16 C27H28N4O8 536 149–151 0.47 91
17 C27H26N4O8 534 140–142 0.25 79
18 C26H25ClN4O7 540 150–153 0.59 73
19 C26H26N4O7 506 144–146 0.47 83
20 C26H25ClN4O7 540 151–153 0.55 75
21 C28H30N4O9 566 146–148 0.66 85
22 C26H26N4O8 522 100–102 0.61 74
23 C26H25ClN4O7 540 141–143 0.56 77
24 C28H28N4O7 532 143–145 0.53 81




Comp. Minimum inhibitory concentration (MIC)
Bacterial strains Fungal strains
S. aureus B. subtilis E. coli C. albicans A. niger
1 2.19 2.19 2.19 2.19 1.09
2 4.19 2.10 2.10 1.05 1.05
3 2.27 2.27 2.27 1.13 1.13
4 4.33 4.33 8.67 2.17 1.08
5 9.07 1.13 9.07 2.27 1.13
6 2.27 2.27 2.27 2.27 1.13
7 2.28 1.14 2.28 2.28 1.14
8 2.39 2.39 2.39 2.39 1.20
9 2.26 2.26 2.26 2.26 1.13
10 2.18 2.18 2.18 2.18 1.09
11 2.33 1.17 2.33 2.33 1.17
12 2.14 2.14 2.14 2.14 2.14
13 9.33 2.33 9.33 2.33 2.33
14 2.14 2.14 2.14 2.14 2.14
15 4.16 1.04 2.08 1.04 1.04
16 4.66 1.17 2.33 2.33 2.33
17 2.34 1.17 2.34 2.34 1.17
18 4.63 0.58 2.31 2.31 2.31
19 2.47 1.24 2.47 2.47 1.24
20 2.31 1.16 2.31 1.16 2.31
21 2.21 1.10 1.10 1.10 1.10
22 2.39 2.39 2.39 1.20 1.20
23 4.63 1.16 2.31 2.31 2.31
24 2.35 1.17 2.35 1.17 1.17

















Fig. 1 Standard graph of ascorbic acid
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improved the antibacterial activity of the synthe-
sized compounds against E. coli.
  • Presence of electron withdrawing groups (–Br, –Cl, 
Compounds 12, 14, 15 and 18) on benzylidene portion 
improved the antimicrobial activity of the synthesized 
compounds against S. aureus, B. subtilis, A. niger and C. 
albicans.
  • Presence of electron releasing groups (trimethoxy and 
p-OCH3, Compounds 2 and 16) on benzylidene por-
tion enhanced the antioxidant activity.
  • Presence of electron withdrawing group (o-Cl, Com-
pound 23) on benzylidene portion improved the anti-
cancer activity of the synthesized compounds against 
human breast (MCF-7) cancer cell line.
Experimental section
Synthesized pyrimidine derivatives followed the general 
procedure discussed in synthetic (Scheme  1). All rea-
gents and solvents used in study were of both labora-
tory and analytical grade and procured from commercial 
market. Reaction steps forward was observed by thin 
layer chromatography making use of commercial silica 
gel plates. Melting points were tested in open capillary 
tubes method. 1H nuclear magnetic resonance (1H-NMR) 
spectral study demonstrated by Bruker Avance 400 NMR 
spectrometer in appropriate DMSO-deuterated solvents 
and are expressed in parts per million (δ, ppm) downfield 
from tetramethyl silane (internal standard). 1H-NMR 
data are given as multiplicity (s, singlet; d, doublet; t, tri-
plet; m, multiplet) and number of protons. Infrared (IR) 
spectra were recorded on Bruker 12060280, Software: 
OPUS 7.2.139.1294 spectrophotometer.
General procedure for synthesized pyrimidine analogues
Step 1: intermediate‑I A mixture of 3-oxo-N-phenylb-
utanamide (0.02 mol), guanidine nitrate (0.030 mol) and 
corresponding aldehyde (0.02 mol) in the round bottom 
flask with 100  ml methanol and then added aluminum 
chloride (0.006  mol) with 4–5 drops of concentrated 
hydrochloric acid after that the reaction mixture was 
refluxed for 10–11 h. before completion of the reaction we 
had been checked the reaction with every 30 min by TLC 
plats with suitable solvent system (benzene). After com-
pletion of the reaction the reaction mixture was cooled 
at room temperature and poured into ice cold water with 
vigorous stirring, filtered and recrystallized with metha-
nol [11].
Step 2: final analogues (1–17) The intermediate-1 
(0.02 mol, synthesized in previous step-1), sodium ben-
zoate (4 gm), 6-(hydroxymethyl)-tetrahydro-2H-pyran-
2,3,4,5-tetraol (0.02  mol), ethyl acetoacetate (15  ml), 


























Fig. 3 IC50 values of compounds 2 and 16 compared to ascorbic 
acid
Table 3 Antioxidant activity of the synthesized analogous
Comp. % Inhibition IC50 µg/ml
25 µg/ml 50 µg/ml 75 µg/ml 100 µg/ml
1 30.56 42.68 55.52 76.45 60.30
2 37.25 51.23 67.34 89.45 46.31
3 20.62 35.93 56.24 69.85 68.90
4 15.71 33.96 43.59 65.21 78.60
5 21.73 37.39 58.72 73.24 65.60
6 25.65 30.95 51.34 67.28 72.70
7 14.59 24.78 47.64 59.45 83.20
8 26.34 37.31 55.28 72.52 65.80
9 32.62 48.28 65.21 82.16 51.83
10 28.89 45.85 60.27 72.56 59.20
11 26.73 47.19 63.81 79.34 56.40
12 17.62 42.95 56.57 68.28 67.80
13 32.47 47.61 64.92 78.52 53.06
14 19.53 41.63 61.57 74.82 63.30
15 22.68 39.91 57.74 71.73 65.40
16 35.95 53.23 62.58 78.84 48.81
17 24.64 43.98 61.37 74.81 60.70
18 32.94 48.92 59.38 72.49 55.90
19 19.62 43.81 61.52 74.49 62.60
20 21.71 34.61 56.70 75.82 66.24
21 15.25 33.41 47.43 65.51 77.00
22 19.26 33.16 50.16 69.25 72.90
23 23.67 47.28 65.11 78.26 57.65
24 23.68 47.28 56.14 72.61 62.60
Ascorbic 
acid
39.52 55.74 68.25 93.61 42.52
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(0.030  mol) were taken in round bottom flask and 
refluxed with for 6–7 h (controlled temperature at 140–
142 °C) before completion of the reaction, we had been 
checked the reaction with every 30  min by TLC plats 
with suitable solvent system (benzene). After comple-
tion of the reaction the reaction mixture was cooled at 
room temperature and poured into ice cold water to 
yielded solid precipitate, filtered and recrystallized with 
methanol.
Spectral analysis determined by
FT-IR (KBr pellets, cm−1) and 1H-NMR/13C-NMR 





pyrimidine-6-carboxamide) IR: {3060 (C–H st.), 1596 (C=C 
st.), 712 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3340 
(N–H st., 2° amide), {1630 (N=CH st.), 1313 (C–N st.) of pn}, 
2831 (C–H st., cyclic ether), 1093 (C–O–C st., aryl ether), 
3340 (O–H st., polyhydroxy); 1H-NMR (DMSO-d6, δ ppm): 
7.16–7.65 (m, 11H, Ar–H), 2.13 (s, 1H, NH), 8.03 (s, 1H, 
NH of 2o amide), 3.47-4.26 (m, 5H, CH of tetrahydropyran), 
2.20 {s, 4H, (OH)4}. 13C-NMR (DMSO-d6, δ ppm): 24.5, 
51.3, 77.4, 78.3, 98.7, 115.3, 118.4, 121.5, 130.6, 146.3, 163.4, 
121.3, 123.4, 122.8, 137.4, 127.1, 128.8, 133.6, 153.6, 119.3; MS 




pyrimidine-6-carboxamide) IR: {3062 (C–H st.), 1596 
(C=C st.), 694 (C–C st.,) of aromatic ring}, 1630 (C = O 
st.), 3321 (N–H st., 2o amide), {1630 (N=CH st.), 1244 
(C–N st.) of pn}, 2779 (C–H st., cyclic ether), 1126 
(C–O–C st., aryl ether), 3321 (O–H st., polyhydroxy), 
1244 (C–O–C st., –OCH3); 1H-NMR (DMSO-d6, δ 
ppm): 7.45–7.49 7H, Ar–H), 7.49 (d, J = 8 Hz, 2H, Ar–H), 
8.25 (s, 1H, NH of 2° amide), 4.20–4.22 (m, 5H, CH of tet-
rahydropyran), 2.10 {s, 4H, (OH)4}, 3.86 {s, 9H, (OCH3)3}; 
13C-NMR (DMSO-d6, δ ppm): 21.3, 72.3, 76.4, 99.5, 56.2, 
60.1, 104.2, 120.3, 125.4, 128.6, 128.9, 128.0, 130.1, 137.2, 




[1,2-a]pyrimidine-6-carboxamide) IR: {3073 (C–H 
st.), 1598 (C=C st.), 716 (C–C st.) of aromatic ring}, 
1630 (C=O st., 2˚amide), 1711 (C=O st., aryl ketone), 
3354 (N–H st., 2° amide), {1711 (N=CH st.), 1347 (C–N 
st.) of pn}, 2779 (C–H st., cyclic ether), 1107 (C–O–C 
st., aryl ether), 3354 (O–H st., polyhydroxy), 1347 (NO2 
st., phenyl nucleus), 854 (C–N st., C6H5NO2); 1H-NMR 
(DMSO-d6, δ ppm): 7.28–8.09 (m, 9H, Ar–H), 1.97 (s, 
1H, NH), 8.10 (s, 1H, NH of 2° amide), 3.47–4.25 (m, 5H, 
CH of tetrahydropyran), 2.12 {s, 4H, (OH)4}; 13C-NMR 
(DMSO-d6, δ ppm): 21.2, 71.3, 76.2, 98.5, 59.2, 120.3, 
125.4, 128.7, 128.9, 128.0, 130.1, 137.2, 149.2, 152.3, 




pyrimidine-6-carboxamide) IR: {2977 (C–H st.), 1590 
Table 5 Anticancer activity of  the selected synthesized 
analogous
Where aGI50 ≤ µMolar is considered to be active, LC50, concentration of drug 
causing 50% cell kill; GI50, concentration of drug causing 50% inhibition of cell 
growth; TGI, concentration of drug causing total inhibition of cell growth; ADR 
adriamycin, positive control compound




1 >100 >100 82.82
3 >100 >100 75.3
10 NE NE NE
13 >100 >100 54
15 >100 >100 97.9
18 >100 >100 66.8
20 >100 >100 80.08
22 >100 >100 94.5
23 >100 73.05 34.78
MNP >100 >100 >100















Growth Curve: Human Breast Cancer 
Cell Line MCF-7


















Growth Curve: Human Breast Cancer 
Cell Line MCF-7
PF-20 PF-22 PF-23 MNP ADR
Fig. 4 Graph plotted between tested compound and standard drug
Page 8 of 11Rani et al. Chemistry Central Journal  (2017) 11:16 
(C=C st.), 708 (C–C st.) of aromatic ring}, 1650 (C=O 
st.,), 3283 (N–H st., 2° amide), {1650 (N=CH st., pn), 
1255 (C–N st.) of pn}, 2738 (C–H st., cyclic ether), 1076 
(C–O–C st., aryl ether), 3283 (O–H st., polyhydroxy), 2823 
(C–H st., aliphatic chain), 1183 (C–C st., aliphatic chain); 
1H-NMR (DMSO-d6, δ ppm): 6.63–7.49 (m, 9H, Ar–H), 
2.11 (s, 1H, NH), 8.09 (s, 1H, NH of 2° amide), 6.7 (s, 1H, 
ethylene), 3.45–5.39 (m, 5H, CH of tetrahydropyran), 2.19 
{s, 4H, (OH)4}, 1.19 {(t, 6H, (CH3)2, 3.43 (q, 4H, (CH2)2 of 
(C2H5)2}; 13C-NMR (DMSO-d6, δ ppm): 12.3, 21.3, 47.9, 
72.3, 77.2, 98.5, 59.2, 112.7, 120.3, 121.9, 125.4, 128.5, 128.0, 





pyrimidine-6-carboxamide) IR: {3062 (C–H st.), 1597 
(C=C st.), 693 (C–C st.) of aromatic ring}, 1630 (C=O 
st.,), 3307 (N–H st., 2° amide), {1630 (N=CH st.), 1330 
(C–N st.) of pn}, 2779 (C–H st., cyclic ether), 1125 
(C–O–C st., aryl ether), 3307 (O–H st., polyhydroxy), 
1350 (NO2 st., phenyl nucleus), 841 (C–N st., C6H5NO2); 
1H-NMR (DMSO-d6, δ ppm): 7.28–8.09 (m, 9H, Ar–H), 
2.12 (s, 1H, NH), 8.10 (s, 1H, NH of 2o amide), 3.47–4.23 
(m, 5H, CH of tetrahydropyran), 2.19 {s, 4H, (OH)4}; 13C-
NMR (DMSO-d6, δ ppm): 21.2, 72.3, 76.2, 98.5, 59.2, 
120.3, 121.1, 125.4, 128.7, 128.9, 128.0, 129.1, 130.1, 133.3, 





pyrimidine-6-carboxamide) IR: {2933 (C–H st.), 1597 
(C=C st.), 691 (C–C st.) of aromatic ring}, 1630 (C=O 
st.,), 3385 (N–H st., 2° amide), {1630 (N=CH st., pn), 
1245 (C–N st.) of pn}, 2779 (C–H st., cyclic ether), 1096 
(C–O–C st., aryl ether), 3385 (O–H st., polyhydroxy), 
1352 (NO2 st.), 855 (C–N st., C6H5NO2); 1H-NMR 
(DMSO-d6, δ ppm): 7.28–7.61 (m, 9H, Ar–H), 2.08(s, 
1H, NH), 8.11 (s, 1H, NH of 2° amide), 1.88(s, 3H, CH3), 
3.47–4.57 (m, 5H, CH of tetrahydropyran), 2.11 {s, 4H, 
(OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.4, 73.1, 76.2, 
94.5, 120.5, 121.2, 125.4, 129.7, 127.2, 129.1, 127.1, 130.1, 





pyrimidine-6-carboxamide) IR: {3026 (C–H st.), 1559 
(C=C st.), 714 (C–C st.) of aromatic ring}, 1595 (C=O 
st., 2° amide), 1711 (C=O st., aryl ketone), 3062 (N–H st., 
2° amide), {1711 (N=CH st.), 1248 (C–N st.) of pn}, 2814 
(C–H st., cyclic ether), 1070 (C–O–C st., aryl ether), 3399 
(O–H st., polyhydroxy), 2934 (C–H st., aliphatic chain); 1H-
NMR (DMSO-d6, δ ppm): 6.65–7.62 (m, 9H, Ar–H), 2.11 
(s, 1H, NH), 8.09 (s, 1H, NH of 2° amide), 6.74 (s, 1H, eth-
ylene), 3.47–4.41 (m, 5H, CH of tetrahydropyran), 2.19 {s, 
4H, (OH)4}, 3.06 {s, 6H, of (CH3)2}; 13C-NMR (DMSO-d6, 
δ ppm): 21.4, 41.0, 55.1, 70.1, 73.1, 76.2, 94.8, 120.5, 121.3, 
124.1, 125.4, 129.0, 127.8, 127.1, 130.4, 132.6, 135.2, 147.2, 
163.1; MS ES + (ToF): m/z 549 [M++1].
Compound 8 (5-(4-Hydroxyphenyl)-7-methyl-3-oxo- 
N-phenyl-2-((3,4,5,6-tetrahydroxytetrahydro-2H- 
pyran-2-yl)methylene)-1,2,3,5-tetrahydroimidazo[1,2-
a]pyrimidine-6-carboxamide) IR: {3064 (C–H st.), 1596 
(C=C st.), 714 (C–C st.) of aromatic ring}, 1596 (C=O 
st., 2° amide), 1712 (C=O st., aryl ketone), 3385 (N–H st., 





Increased antimicrobial activity against
















activity against E. coli.
Enhanced the
antioxidant activity.
Electron withdrawing group (o-Cl) improved
the anticancer activity against human breast
(MCF-7) cancer cell line.
Fig. 5 Structural requirements for the antimicrobial, anticancer and antioxidant activities of synthesized derivatives
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(C–H st., cyclic ether), 1083 (C–O–C st., aryl ether), 3385 
(O–H st., polyhydroxy), 3385 (OH st., phenyl nucleus); 
1H-NMR (DMSO-d6, δ ppm): 7.44–7.58 (m, 9H, Ar–H), 
2.06 (s, 1H, NH), 8.07 (s, 1H, NH 2° amide), 3.45–4.96 
(m, 5H, CH, tetrahydropyran), 2.16 {s, 4H, (OH)4}, 4.96 
(s, 1H, Ar–OH); 13C-NMR (DMSO-d6, δ ppm): 21.2, 
55.1, 71.1, 73.1, 76.2, 94.3, 113.6, 120.5, 121.3, 124.1, 
125.4, 128.1, 129.0, 135.2, 147.2, 152.1, 156.2, 163.1; MS 
ES + (ToF): m/z 522 [M++1].




IR: {2967 (C–H st.), 1595 (C=C st.), 713 (C–C st.) of aro-
matic ring}, 1595 (C=O st.,), 3422 (N–H st., 2° amide), 
{1595 (N=CH st.), 1249 (C–N st.) of pn}, 2832 (C–H st., 
cyclic ether), 1070 (C–O–C st., aryl ether), 3422 (O–H 
st., polyhydroxy), 3422 (OH st., phenyl nucleus), 1249 
(C–O–C st., –OCH3); 1H-NMR (DMSO-d6, δ ppm): 
2.10 (s, 1H, NH), 5.71 (s, 1H, CH of pyrimidine), 3.46–
4.85 (m, 5H, CH of tetrahydropyran), 2.18 {s, 4H, (OH)4}, 
3.76 (s, 3H, OCH3); 13C-NMR (DMSO-d6, δ ppm): 21.3, 
55.3, 56.1, 70.1, 73.1, 76.2, 94.8, 113.6, 120.6, 116.3, 121.4, 
124.4, 125.1, 129.0, 130.2, 135.9, 136.2, 143.2, 151.2, 




pyrimidine-6-carboxamide) IR: {2834 (C–H st.), 1594 (C=C 
st.), 703 (C–C st.) of aromatic ring}, 1594 (C=O st.,), 3380 
(N–H st., 2° amide), {1594 (N=CH st.), 1350 (C–N st.) of pn}, 
2735 (C–H st., cyclic ether), 1090 (C–O–C st., aryl ether), 
3380 (O–H st., polyhydroxy), 758 (C–Cl st., phenyl nucleus); 
1H-NMR (DMSO-d6, δ ppm): 6.94–7.50 (m, 8H, Ar–H), 
2.08 (s, 1H, NH), 8.10 (s, 1H, NH of 2° amide), 6.21 (s, 1H, 
ethylene), 3.47–5.00 (m, 5H, CH of tetrahydropyran), 2.12 {s, 
4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.2, 45.2, 70.0, 
73.1, 76.2, 94.9, 120.6, 121.4, 124.4, 125.1, 126.2, 129.0, 130.2, 





pyrimidine-6-carboxamide) IR: {3063 (C–H st.), 1595 (C=C 
st.), 710 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3397 
(N–H st., 2° amide), {1630 (N=CH st.), 1247 (C–N st.) of pn}, 
2832 (C–H st., cyclic ether), 1050 (C–O–C st., aryl ether), 
3397 (O–H st., polyhydroxy), 1247 (C–O–C st., –OCH3); 1H-
NMR (DMSO-d6, δ ppm): 6.89–7.58 (m, 9H, Ar–H), 2.04 (s, 
1H, NH), 6.88 (s, 1H, ethylene), 3.44–4.97 (m, 5H, CH of tet-
rahydropyran), 2.07 {s, 4H, (OH)4}, 3.70 (s, 3H, OCH3); 13C-
NMR (DMSO-d6, δ ppm): 21.1, 45.2, 70.3, 73.1, 76.2, 94.8, 
114.1, 120.6, 121.4, 124.4, 125.1, 127.2, 128.2, 129.0, 130.2, 





pyrimidine-6-carboxamide) IR: {3064 (C–H st.), 1596 
(C=C st.), 712 (C–C st.) of aromatic ring}, 1596 (C=O st.,), 
3386 (N–H st., 2° amide), {1596 (N=CH st.), 1253 (C–N 
st.) of pn}, 2832 (C–H st., cyclic ether), 1071 (C–O–C st., 
aryl ether), 3386 (O–H st., polyhydroxy), 510 (C–Br st.); 
1H-NMR (DMSO-d6, δ ppm): 7.43–7.63 (m, 9H, Ar–H), 
7.63 (d, J = 8 Hz, 2H, Ar–H), 8.09 (s, 1H, NH of 2° amide), 
1.97 (s, 1H, NH), 1.84 (s, 3H, CH3), 6.18 (s, 1H, CH of eth-
ylene), 3.47–4.38 (m, 5H, CH of tetrahydropyran), 2.11 {s, 
4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.4, 54.8, 70.3, 
73.1, 76.1, 94.7, 120.6, 121.4, 124.4, 125.1, 126.2, 129.0, 130.2, 





pyrimidine-6-carboxamide) IR: {3062 (C–H st.), 1595 (C=C 
st.), 712 (C–C st.) of aromatic ring}, 1631 (C=O st., 2° amide), 
1716 (C=O st., aryl ketone), 3385 (N–H st., 2° amide), {1631 
(N=CH st.), 1247 (C–N st.) of pn}, 2831 (C–H st., cyclic 
ether), 1070 (C–O–C st., aryl ether), 3385 (O–H st., polyhy-
droxy), 1247 (C–O–C st., –OCH3); 1H-NMR (DMSO-d6, δ 
ppm): 7.25–7.48 (m, 9H, Ar–H), 1.96 (s, 1H, NH), 8.0 (s, 1H, 
NH of 2° amide), 3.45–4.99 (m, 5H, CH of tetrahydropyran), 
2.11 {s, 4H, (OH)4}, 3.76 (s, 3H, OCH3); 13C-NMR (DMSO-
d6, δ ppm): 21.3, 55.2, 55.8, 70.3, 73.1, 76.2, 94.9, 111.0, 197.0, 
120.6, 121.5, 124.4, 125.1, 129.0, 130.2, 133.4, 135.2, 140.2, 




pyrimidine-6-carboxamide) IR: {3058 (C–H st.), 1595 
(C=C st.), 709 (C–C st.) of aromatic ring}, 1631 (C=O 
st., 2° amide), 1715 (C=O st., aryl ketone), 3333 (N–H st., 
2° amide), {1631 (N=CH st.), 1315 (C–N st.) of pn}, 2831 
(C–H st., cyclic ether), 1072 (C–O–C st., aryl ether), 3333 
(O–H st., polyhydroxy), 509 (C–Br st.); 1H-NMR (DMSO-
d6, δ ppm): 7.14–7.64 (m, 9H, Ar–H), 7.66 (d, J = 8 Hz, 2H, 
Ar–H), 8.1 (s, 1H, NH of 2° amide), 2.19 (s, 1H, NH), 1.82 (s, 
3H, CH3), 3.47–5.00 (m, 5H, CH of tetrahydropyran), 2.13 {s, 
4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.3, 55.0, 70.3, 
73.1, 76.2, 94.8, 197.0, 120.6, 121.5, 124.4, 125.1, 129.0, 130.2, 
131.1, 133.4, 135.7, 142.2, 146.2, 152.7, 162.1, 163.3; MS 
ES + (ToF): m/z 584 [M++1].
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IR: {3062 (C–H st.), 1596 (C=C st.), 691 (C–C st.) of 
aromatic ring}, 1631 (C=O st., 2° amide), 1712 (C=O st., 
aryl ketone), 3332 (N–H st., 2° amide), {1631 (N=CH st.), 
1282 (C–N st.) of pn}, 2832 (C–H st., cyclic ether), 1070 
(C–O–C st., aryl ether), 3332 (O–H st., polyhydroxy), 
3332 (OH st., phenyl), 543 (C–Br st.); 1H-NMR (DMSO-
d6, δppm): 7.29–7.63 (m, 8H, Ar–H), 7.49 (d, J = 8 Hz, 
2H, Ar–H), 2.13 (s, 1H, NH), 8.1(s, 1H, NH of 2° amide), 
1.71 (s, 3H, CH3), 6.6 (s, 1H of ethylene), 3.79–5.12 (m, 
5H, CH of tetrahydropyran), 1.98 {s, 4H, (OH)4}, 5.07 
(s, 1H, of Ar–OH); 13C-NMR (DMSO-d6, δ ppm): 21.3, 
44.2, 70.3, 73.4, 76.2, 94.9, 117.0, 115.3, 120.6, 121.4, 
124.1, 125.1, 129.0, 130.2, 131.2, 133.4, 135.2, 146.2, 




pyrimidine-6-carboxamide) IR: {3062 (C–H st.), 1595 (C=C 
st.), 691 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3385 
(N–H st., 2° amide), {1630 (N=CH st.), 1247 (C–N st.) of pn}, 
2831 (C–H st., cyclic ether), 1072 (C–O–C st., aryl ether), 
3385 (O–H st., polyhydroxy), 1247 (C–O–C st., –OCH3); 1H-
NMR (DMSO-d6, δ ppm): 7.28–7.45 (m, 9H, Ar–H), 8.04 
(s, 1H, NH of 2o amide), 4.15–4.21(m, 5H, CH of tetrahydro-
pyran), 2.40 {s, 4H, (OH)4}, 3.44 (s, 3H, OCH3), 1.71 (s, 3H, 
CH3); 13C-NMR (DMSO-d6, δ ppm): 21.1, 55.0, 55.8, 70.3, 
73.1, 76.2, 94.5, 114.0, 120.6, 121.5, 124.4, 125.1, 128.3, 129.0, 





pyrimidine-6-carboxamide) IR: {3063 (C–H st.), 1595 (C=C 
st.), 690 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3384 
(N–H st., 2° amide), {1630 (N=CH st.), 1244 (C–N st.) of 
pn}, 2831 (C–H st., cyclic ether), 1071 (C–O–C st., aryl 
ether), 3384 (O–H st., polyhydroxy), 2716 (C–H st., CHO), 
1364 (C–C st., CHO group); 1H-NMR (DMSO-d6, δ ppm): 
7.23–7.62 (m, 9H, Ar–H), 1.97 (s, 1H, NH), 8.16 (s, 1H, NH 
of 2° amide), 3.47–4.99 (m, 5H, CH of tetrahydropyran), 2.12 
{s, 4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.3, 55.3, 
70.4, 73.1, 76.2, 94.8, 120.6, 121.4, 124.4, 125.1, 127.3, 129.0, 
130.2, 134.3, 135.2, 146.2, 149.3, 152.7, 162.1, 163.3, 192.2; MS 




pyrimidine-6-carboxamide) IR: {3057 (C–H st.), 1596 (C=C 
st.), 689 (C–C st.) of aromatic ring}, 1666 (C=O st., 2° amide), 
1717 (C=O st., aryl ketone), 3327 (N–H st., 2° amide), 
{1666 (N=CH st.), 1315 (C–N st.) of pn}, 2830 (C–H st., 
cyclic ether), 1082 (C–O–C st., aryl ether), 3327 (O–H st., 
polyhydroxy), 758 (C–Cl st.); 1H-NMR (DMSO-d6, δ ppm): 
7.28–7.63(m, 9H, Ar–H), 7.52 (d, J = 4 Hz, 2H, Ar–H), 2.13 
(s, 1H, NH), 8.11(s, 1H, NH of 2° amide), 1.85 (s, 3H, CH3), 
3.47–5.00 (m, 5H, CH of tetrahydropyran), 1.97 {s, 4H, 
(OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.3, 55.3, 70.4, 73.1, 
76.2, 94.8, 120.6, 121.4, 124.4, 125.1, 126.2, 129.0, 130.2, 135.2, 





idine-6-carboxamide): IR-{3057 (C–H st.), 1594 (C=C 
st.), 706 (C–C st.) of aromatic ring}, 1664 (C=O st., 2° 
amide), 1714 (C=O st., aryl ketone), 3335 (N–H st., 2° 
amide), {1664 (N=CH st.), 1315 (C–N st.) of pn}, 2831 
(C–H st., cyclic ether), 1073 (C–O–C st., aryl ether), 
3335 (O–H st., polyhydroxy), 3335 (OH st., phenyl), 2616 
(C-H st., CHO), 1364 (C–C st., C6H5CHO); 1H-NMR 
(DMSO-d6, δ ppm): 7.48–7.64 (m, 10H, Ar–H), 1.96 (s, 
1H, NH), 8.1 (s, 1H, NH of 2° amide), 1.84 (s, 3H, CH3), 
3.75–4.24 (m, 5H, CH of tetrahydropyran), 2.12 {s, 4H, 
(OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.0, 55.1, 70.3, 
73.1, 76.2, 94.2, 120.5, 121.2, 124.4, 125.1, 126.2, 128.3, 





pyrimidine-6-carboxamide) IR: 2958 (C–H st.), 1594 (C=C 
st.), 709 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3420 
(N–H st., 2° amide), {1630 (N=CH st.), 1177 (C–N st.) of 
pn}, 2831 (C–H st., cyclic ether), 1090 (C–O–C st., aryl 
ether), 3420 (O–H st., polyhydroxy), 775 (C–Cl st.); 1H-NMR 
(DMSO-d6, δ ppm): 7.29–7.64 (m, 9H, Ar–H), 2.07 (s, 1H, 
NH), 8.0(s, 1H, NH of 2° amide), 1.83 (s, 3H, CH3), 6.08 (s, 
1H of ethylene), 3.47–4.87 (m, 5H of CH of tetrahydropyran), 
2.09 {s, 4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 21.3, 
55.0, 70.4, 73.1, 77.2, 94.8, 120.6, 121.4, 124.4, 125.1, 128.3, 
128.5, 129.0, 130.2, 135.2, 141.4, 146.2, 152.7, 162.1, 163.1; MS 
ES + (ToF): m/z 540 [M++1].




IR: {3027 (C–H st.), 1559 (C=C st.), 710 (C–C st.) of 
aromatic ring}, 1594 (C=O st., 2° amide), 1713 (C=O 
st., aryl ketone), 3416 (N–H st., 2° amide), {1713 (N=CH 
st.), 1316 (C–N st.) of pn}, 2831 (C–H st., cyclic ether), 
1071 (C–O–C st., aryl ether), 3416 (O–H st., polyhy-
droxy), 3416 (OH st., phenyl nucleus), 2831 (C–H st., ali-
phatic chain), 1175 (C–C st., aliphatic chain); 1H-NMR 
(DMSO-d6, δ ppm): 7.28–7.63 (m, 8H, Ar–H), 7.50 (d, 
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J = 8 Hz, 2H, Ar–H), 2.12 (s, 1H, NH), 8.10 (s, 1H, NH 2° 
amide), 1.83 (s, 3H, CH3), 3.47–4.99 (m, 5H, CH of tet-
rahydropyran), 1.97 {s, 4H, (OH)4}, 1.33 (dt, J = 8 Hz, 3H, 
CH3), 4.21 (d, J =  8  Hz, 2H, CH2); 13C-NMR (DMSO-
d6, δ ppm): 21.5, 65.1, 70.2, 73.4, 76.2, 77.5, 94.7, 116.3, 
120.1, 121.5, 130.6, 162.3, 143.1, 146.4, 163.4, 121.3,124.4, 
125.8, 135.4, 129.1, 128.8, 136.5, 137.7, 148.3; MS 




pyrimidine-6-carboxamide) IR: {3060 (C–H st.), 1596 (C=C 
st.), 691 (C–C st.) of aromatic ring}, 1630 (C=O st.,), 3333 
(N–H st., 2° amide), {1630 (N=CH st.), 1294 (C–N st.) of pn}, 
2832 (C–H st., cyclic ether), 1103 (C–O–C st., aryl ether), 
3333 (O–H st., polyhydroxy), 3333 (OH st., phenyl nucleus); 
1H-NMR (DMSO-d6, δ ppm): 7.28 (m, 9H, Ar–H), 8.13 (s, 
1H, NH of 2° amide), 3.47–4.24 (m, 5H, CH of tetrahydro-
pyran), 2.19 {s, 4H, (OH)4}; 13C-NMR (DMSO-d6, δ ppm): 
21.2, 44.2, 70.0, 73.1, 76.2, 94.9, 115.8, 120.6, 130.4, 121.4, 
122.6, 124.4, 125.1, 128.7, 129.0, 130.3, 135.2, 146.2, 152.7, 
154.2, 162.4; MS ES + (ToF): m/z 522 [M++1].
Compound 23 (5-(2-Chlorophenyl)-7-methyl-3-oxo- 
N - p h e n y l - 2 - ( ( 3 , 4 , 5 , 6 - t e t r a h y d r o x y t e t r a h y -
d r o - 2 H - p y r a n - 2 - y l ) m e t h y l e n e ) - 1 , 2 , 3 , 5 -
tetrahydroimidazo[1,2-a]pyrimidine-6-carboxamide) 
IR: {3059 (C–H st.), 1594 (C=C st.), 708 (C–C st.) of aro-
matic ring}, 1594 (C=O st.,), 3383 (N–H st., 2° amide), 
{1594 (N=CH st.), 1316 (C–N st.) of pn}, 2830 (C–H st., 
cyclic ether), 1071 (C–O–C st., aryl ether), 3383 (O–H 
st., polyhydroxy), 758 (C–Cl st.); 1H-NMR (DMSO-d6, δ 
ppm): 7.35–7.64 (m, 9H, Ar–H), 2.13 (s, 1H, NH), 8.1 (s, 
1H, NH of 2° amide), 3.47–4.69 (m, 5H, CH of tetrahy-
dropyran), 2.13 {s, 4H, (OH)4}; 13C-NMR (DMSO-d6, δ 
ppm): 21.2, 45.9, 70.0, 73.1, 76.1, 94.8, 120.5, 130.4, 121.6, 
122.6, 125.1, 126.1, 128.7, 129.0, 135.8, 146.2, 152.7, 162.6, 




6-carboxamide) IR: {2967 (C–H st.), 1594 (C=C st.), 710 
(C–C st.) of aromatic ring}, 1630 (C=O st.,), 3422 (N–H st., 2° 
amide), {1630 (N=CH st.), 1271 (C–N st.) of pn}, 2831 (C–H 
st., cyclic ether), 1070 (C–O–C st., aryl ether), 3422 (O–H st., 
polyhydroxy), {2831 (C–H st.), 1176 (C–C st.), 1630 (C=C 
st.) of aliphatic chain}; 1H-NMR (DMSO-d6, δ ppm): 7.33-
7.63 (m, 10H, Ar–H), 2.09 (s, 1H, NH), 8.09 (s, 1H, NH of 2° 
amide), 6.69 (s, 1H, ethylene), 3.48–5.04 (m, 5H, CH of tet-
rahydropyran), 2.1 {s, 4H, (OH)4}, 6.16 {d, 1H,(CH)2; 6.51 (d, 
1H, (CH)b of aliphatic chain}; 13C-NMR (DMSO-d6, δ ppm): 
21.5, 73.4, 77.5, 79.3, 98.7, 122.5, 130.6, 162.3, 146.4, 163.4, 
121.3, 123.4, 125.8, 137.4, 127.1, 128.8, 133.6, 136.5, 137.7 
153.6, 119.3; MS ES + (ToF): m/z 532 [M++1].
Conclusions
Summarizing, we may conclude that the synthesized com-
pounds 12, 14, 15, 18 and 21 displayed appreciable anti-
bacterial and antifungal activities and compounds 2 and 16 
exhibited excellent in vitro antioxidant activity due to the 
presence of electron releasing groups on benzylidene por-
tion and anticancer activity indicated that compound 23 
was found to be most active against human breast (MCF-7) 
cancer cell line due to the presence of electron withdrawing 
groups (o-Cl) on benzylidene portion. These compounds 
may be used as lead for the development of novel therapeu-
tic agents.
Authors’ contributions
PKV designed research and JR performed research and MS and SK analyzed 
the spectral data and biological data and wrote the paper. All authors read and 
approved the final manuscript.
Acknowledgements
Thank to Prof. B. Narasimhan, Department of Pharmaceutical Sciences, M. D. 
University, Rohtak for kind support for providing chemicals.
Competing interests
The authors declare that they have no competing interests.
Received: 19 December 2016   Accepted: 1 February 2017
References
 1. Tomma JH, Khazaal MS, Al-Dujaili AH (2014) Synthesis and characterization 
of novel Schiff bases containing pyrimidine unit. Arab J Chem 7:157–163
 2. Kandile NG, Mohamed MI, Zaky H, Mohamed HM (2009) Novel pyridazine 
derivatives: synthesis and antimicrobial activity evaluation. Eur J Med Chem 
44:1989–1996
 3. Sarkar A, Kumar KA, Dutta NK, Chakraborty P, Dastidar SG (2003) Evaluation 
of in vitro and in vivo antibacterial activity of dobutamine hydrochloride. 
Indian J Med Microbiol 21:172–178
 4. Gold HS, Moellering RC (1996) Antimicrobial drug resistance. N Engl J Med 
335:1445–1453
 5. Sawant RL, Bansode CA, Wadekar JB (2013) In vitro anti-inflammatory 
potential and QSAR analysis of oxazolo/thiazolo pyrimidine derivatives. Med 
Chem Res 22:1884–1889
 6. Emami S, Foroumadi A, Falahati M, Loffali E, Rajabalian S, Ebrahimi SA, 
Farahyar S, Shafiee A (2008) 2-Hydroxy phenacyl azoles and related azolium 
derivative as antifungal agents. Bioorg Med Chem Lett 18:141–146
 7. Gursoy-Kol O, Ayazoglu E (2014) Antioxidant activities and acidic properties 
of some novel 4-[3,4-di-(4-nitrobenzoxy)-benzylidenamino]-4,5-dihydro-
1H-1,2,4-triazol-5-one derivatives. Arabian J Chem (in press)
 8. Kotaiah Y, Harikrishana N, Nagaraju K, Rao V (2012) Synthesis and antioxidant 
activity of 1,3,4-oxadiazole tagged thieno[2,3-d] pyrimidine derivatives. Eur J 
Med Chem 58:340–345
 9. Liu Z, Wu S, Wang Y, Li R, Wang J, Wang L, Zhao Y, Gong P (2014) Design, Syn-
thesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives 
possessing diaryl semicarbazone scaffolds as potent antitumor agents. Eur J 
Med Chem 87:782–793
 10. Sigroha S, Narasimhan B, Kumar P, Khatkar A, Ramasamy K, Mani V, Mishra 
RK, Majeed ABA (2011) Design, synthesis, antimicrobial, anticancer evalua-
tion, and QSAR studies of 4-(substituted benzylidene-amino)-1,5-dimethyl-
2-phenyl-1,2-dihydropyrazol-3-ones. Med Chem Res (in press)
 11. Cappuccino JG, Sherman N (1999) In microbiology-a laboratory manual, 4th 
edn. Addison Wesley Longman Inc, California
 12. Pharmacopoeia of India, vol. Ӏ (2007) Controller of Publication, Ministry of 
Health Department, Govt. of India, New Delhi, p 37
 13. Mukherjee DPK (2012) Pharmacological screening of herbal drugs. Qual-
ity control of herbal drugs 564
